enGene Therapeutics (ENGN) Return on Capital Employed [ROCE] (2024 - 2026)
enGene Therapeutics' Return on Capital Employed [ROCE] was -50.48% in fiscal Q3 2026 (quarter ended Jul 31, 2026), down 7.56 percentage points from -42.92% a year earlier and down 6.41 percentage points from the prior quarter.
Powered by 
Analysis
enGene Therapeutics (ENGN) Return on Capital Employed [ROCE] (2024 - 2026) Analysis & Trends
For FY2025 (ended Oct 31, 2025), Return on Capital Employed [ROCE] at enGene Therapeutics came in at -52.56%, down 18.78 percentage points from FY2024.
- In earlier fiscal years, Return on Capital Employed [ROCE] was -33.78% in FY2024 (+18.15 pp) and -51.94% in FY2023.
- Quarterly Return on Capital Employed [ROCE] has moved between -61.11% (fiscal Q4 2025) and -21.53% (fiscal Q3 2024) over five years.
- Compared with a year earlier, Return on Capital Employed [ROCE] has declined for six straight quarters, with an average year-over-year change of -13.95 percentage points over the last seven quarters.
- Per Business Quant data, ENGN's Return on Capital Employed [ROCE] in the three fiscal quarters before Q3 2026 was -44.07% (Q2 2026), -50.16% (Q1 2026) and -61.11% (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,359.75 Bn | 1,333.37 Bn | 20.46 Bn | 35.41% |
| 2 | Johnson & Johnson | 688.76 Bn | 608.62 Bn | 17.30 Bn | 17.52% |
| 3 | AbbVie | 521.69 Bn | 489.75 Bn | 13.12 Bn | 21.60% |
| 4 | Merck | 364.31 Bn | 327.31 Bn | 13.19 Bn | 4.65% |
| 5 | Novartis Ag | 306.35 Bn | 279.93 Bn | - | - |
| 6 | Astrazeneca | 285.96 Bn | 259.56 Bn | 13.26 Bn | 9.91% |
| 7 | Amgen | 251.88 Bn | 203.53 Bn | 7.58 Bn | 17.37% |
| 8 | Gilead Sciences | 208.59 Bn | 183.61 Bn | 6.73 Bn | -6.15% |
| 9 | Pfizer | 164.73 Bn | 112.38 Bn | 12.56 Bn | 11.32% |
| 10 | enGene Therapeutics | 161.50 Mn | -832.97 Mn | - | -50.48% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 31, 2026 | -50.48% |
| Apr 30, 2026 | -44.07% |
| Jan 31, 2026 | -50.16% |
| Oct 31, 2025 | -61.11% |
| Jul 31, 2025 | -42.92% |
| Apr 30, 2025 | -34.05% |
| Jan 31, 2025 | -27.36% |
| Oct 31, 2024 | -22.71% |
| Jul 31, 2024 | -21.53% |
| Apr 30, 2024 | -25.27% |
| Jan 31, 2024 | -38.66% |
API Access
enGene Therapeutics Return on Capital Employed [ROCE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=ENGN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-capital-employed-[roce]", "ticker": "ENGN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=ENGN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();